Entrada Therapeutics (TRDA) Corporate presentation summary

Pipeline and strategy

• Five fully owned programs span DMD (ENTR-601-44, -45, -50 and -51) and inherited retinal disease (ENTR-801); partnered VX-670 targets DM1.

• EEV delivery and proprietary active moieties underpin the approach; four clinical data catalysts were expected through H1 2027.

• DMD Phase 1/2 data from ex-U.S. studies are intended to support potential U.S. Accelerated Approval filings, subject to regulatory feedback.

ENTR-601-44 in DMD

• Cohort 1 at 6 mg/kg showed no serious AEs or discontinuations; all TEAEs were mild to moderate, and renal markers were within normal range and comparable to placebo.

• Cohort 1 showed statistically significant TTR improvement of 2.40 seconds and TTRV improvement of 0.09 rises/second versus placebo; positive 10MWR trends were observed.

• Cohort 1 open-label data were expected by year-end 2026; Cohort 2 enrollment at 12 mg/kg was complete, with data expected in Q1 2027.

• Juvenile NHP data underpin expectations for double-digit dystrophin starting at 12 mg/kg in Cohort 2 and continuing at 18 mg/kg in Cohort 3.

ENTR-601-45 in DMD

• Cohort 1 at 5 mg/kg every 6 weeks met its safety and tolerability objective; most TEAEs were mild to moderate, with no discontinuations and renal markers generally within normal range.

• Mean change from baseline was 0.15 in exon skipping versus -0.04 for placebo; MHC-normalized dystrophin change was 0.10 versus -0.02, with nominal p=0.03.

• Cohort 2 enrollment at 10 mg/kg was complete, with dosing ongoing and data expected in H1 2027; Cohort 3 up to 15 mg/kg was expected to follow.

• Cohort 1 exposure at 5 mg/kg was comparable to juvenile NHP exposure at the same dose; dose-proportional projections support expectations for future cohorts.